Stance Capital LLC Takes Position in Cencora, Inc. $COR

Posted by Francis Steltz on Jun 21st, 2026

Stance Capital LLC purchased a new stake in shares of Cencora, Inc. (NYSE:COR – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 10,109 shares of the company’s stock, valued at approximately $3,414,000. Cencora accounts for about 1.3% of Stance Capital LLC’s holdings, making the stock its 17th largest position.

Other institutional investors have also recently bought and sold shares of the company. United Bank lifted its position in shares of Cencora by 4.5% in the second quarter. United Bank now owns 7,032 shares of the company’s stock worth $2,109,000 after purchasing an additional 305 shares in the last quarter. Nebula Research & Development LLC purchased a new position in Cencora during the second quarter valued at approximately $595,000. Treasurer of the State of North Carolina grew its position in Cencora by 7.9% during the second quarter. Treasurer of the State of North Carolina now owns 85,534 shares of the company’s stock valued at $25,647,000 after purchasing an additional 6,244 shares in the last quarter. Diversify Advisory Services LLC increased its stake in Cencora by 94.1% in the 2nd quarter. Diversify Advisory Services LLC now owns 2,585 shares of the company’s stock valued at $747,000 after buying an additional 1,253 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in Cencora by 26.0% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 73,452 shares of the company’s stock valued at $22,025,000 after buying an additional 15,154 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Price Performance

NYSE COR opened at $271.99 on Friday. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The stock has a market capitalization of $52.92 billion, a PE ratio of 20.86, a price-to-earnings-growth ratio of 1.47 and a beta of 0.59. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The company has a 50 day moving average price of $284.59 and a two-hundred day moving average price of $324.35.

Cencora (NYSE:COR – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). The business had revenue of $78.36 billion for the quarter, compared to analyst estimates of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter last year, the company earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities analysts predict that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora declared that its Board of Directors has authorized a share buyback plan on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 3.9% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Friday, May 15th. Cencora’s dividend payout ratio is 18.40%.

Wall Street Analysts Forecast Growth

COR has been the subject of a number of research reports. Morgan Stanley set a $342.00 target price on shares of Cencora in a research note on Friday, May 8th. Evercore set a $360.00 price target on shares of Cencora in a research note on Wednesday, April 8th. Leerink Partners reiterated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Wells Fargo & Company reduced their price objective on Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research report on Monday, May 11th. Finally, Weiss Ratings downgraded Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 22nd. Twelve analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and a consensus price target of $374.00.

Read Our Latest Stock Report on Cencora

Cencora Profile

(Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.